Table of Contents
Patrick Soon-Shiong, a South African-born biopharma billionaire, has seen the market value of his share in ImmunityBio fall by more than $7.3 billion in the past year, as investors continue to sell off shares in the biotech business.
ImmunityBio Inc., originally NantKwest Inc., is a late-stage immunotherapy firm that develops cell and immunological treatments for the treatment of cancer and infectious disorders.
Soon-Shiong, a South African-American transplant surgeon who was instrumental in the development of ImmunityBio, owns 73.2 percent of the biotech business.
Shares in the publicly traded biotech company have fallen from more than $32 per share to less than $10 in the past year, as investors in the U.S. market dumped shares amid efforts to revive the biotech sector by shifting to Africa.
NantSA, one of ImmunityBio’s operating subsidiaries, opened a plant in South Africa last month with the aim to produce up to 1 billion COVID-19 vaccines per year by 2025, in line with Soon-Shiong’s plan to accelerate pharmaceutical, biologic, and vaccine production for patients on the continent.
The factory, which will be located in Cape Town, South Africa’s second-largest city, will be the first in Africa to manufacture COVID-19 vaccines from start to finish. The plant’s commissioning will assist Africa in overcoming its present rank as the world’s least-vaccinated continent.
Despite its aspirations for development in Africa, ImmunityBio’s shares in the nation have dropped by more than 75 percent.
Since Feb. 23, 2021, around a year ago, the company’s share price has gone from $32.38 to $7.08 per share as of the time of writing this article, resulting in a 78-percent loss for shareholders.
Meanwhile, the market value of Soon-73.2 Shiong’s percent share has declined from $9.4 billion on Feb. 23, 2021 to $2.1 billion at the time of writing.
This equates to a total loss of 7.3 billion for the wealthy pharma mogul in the past year. According to the Bloomberg Billionaires Index, his net worth has now dropped from $16.3 billion to $10 billion.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now
